News by ET Net (Dec 2): AIM Vacin, a wholly-owned subsidiary of AIM Vaccine, obtained the approval from the National Medical Products Administration yesterday (December 1) for carrying out clinical trials of ACYW135 Meningococcus Conjugate Vaccine (MCV4).